ClinicalTrials.gg
CompletedNCT01666210Updated Oct 19, 2021Results posted

Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

A Phase 2 interventional study of OTX-DP (Dexamethasone punctum plug) and Placebo Vehicle Punctum Plug in Ocular Inflammation and Pain, sponsored by Ocular Therapeutix, Inc.. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-10-19.

Sponsored by Ocular Therapeutix, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 2,886 studies in Pain with a site in United States — 315 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.

Enrollment
1,333rd of 2,564
60 · median 66
Started
2012
with 138 others
Phase 2
342 of 2,886
26 open now
Registered
1,024th of 2,886
by date

Among the 2,886 studies in Pain with a site in United States, this one is the 1,333rd largest by enrollment of the 2,564 interventional ones that give a count, is one of 139 that started in 2012, is one of 342 in phase 2, and was the 1,024th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

315 of the 2,886 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

310 more — sign in →

All 315 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,886 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone cataract extraction with intra-ocular lens implantation.

03

Conditions studied

  • Ocular Inflammation and Pain

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has provided written , approved by the appropriate institutional review board; and is able to comply with study requirements and visit schedule
  • Is greater than or equal to 21 years of age
  • Has a cataract and is expected to undergo clear corneal cataract surgery with phacoemulsification and implantation of a posterior chamber intraocular lens

Exclusion criteria

Exclusion Criteria:

  • Any intraocular inflammation in the study eye present during the screening slit lamp examination
  • Score greater than "0" on the Ocular Pain Assessment at Screening
  • Compromised immune system or an disease that in the opinion of the Investigator could affect the quality of the ocular surface
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    Dexamethasone Punctum Plug

    Sustained and tapered release of dexamethasone from hydrogel punctum plug following insertion over 30 days

    Drug: OTX-DP (Dexamethasone punctum plug)

  • Placebo comparator
    Placebo Vehicle Punctum Plug

    Placebo punctum plug insertion

    Drug: Placebo Vehicle Punctum Plug

Interventions

  • DrugOTX-DP (Dexamethasone punctum plug)

    Sustained and tapered release of dexamethasone from hydrogel punctum plug

  • DrugPlacebo Vehicle Punctum Plug

    Hydrogel punctum plug without dexamethasone

06

What researchers measure

Primary outcomes

  1. Absence of Cells in Anterior Chamber of Study Eye

    Time frame: Day 8

  2. Absence of Pain in the Study Eye

    Time frame: Day 8

Other outcomes

  1. Adverse Events

    Measure of adverse events over the duration of each subject's participation in the study.

    Time frame: Duration of each individual subject's participation in the study, up to 60 days

07

Results

Posted Apr 27, 2017

Participant flow

Participant flow — Overall Study
MilestoneDexamethasone Punctum PlugPlacebo Vehicle Punctum Plug
Started3030
Completed2829
Not completed21

Outcome measures

PrimaryAbsence of Cells in Anterior Chamber of Study Eye
Time frame:
Day 8
Reported as:
Count of participants · Participants
Absence of Cells in Anterior Chamber of Study Eye
ParticipantsDexamethasone Punctum PlugPlacebo Vehicle Punctum Plug
Absence of Cells in Anterior Chamber of Study Eye63
PrimaryAbsence of Pain in the Study Eye
Time frame:
Day 8
Reported as:
Count of participants · Participants
Absence of Pain in the Study Eye
ParticipantsDexamethasone Punctum PlugPlacebo Vehicle Punctum Plug
Absence of Pain in the Study Eye239
Other pre-specifiedAdverse Events

Measure of adverse events over the duration of each subject's participation in the study.

Time frame:
Duration of each individual subject's participation in the study, up to 60 days
Reported as:
Count of participants · Participants
Adverse Events
ParticipantsDexamethasone Punctum PlugPlacebo Vehicle Punctum Plug
Adverse Events47

Adverse events

Collected over The analyses of safety were based primarily on the incidence of treatment-emergent adverse events up to 60 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dexamethasone Punctum Plug—0/29 (0%)3/29 (10.3%)
Placebo Vehicle Punctum Plug—1/30 (3.3%)10/30 (33.3%)
Most frequent serious events
Most frequent serious events
EventDexamethasone Punctum PlugPlacebo Vehicle Punctum Plug
SyncopeGeneral disorders0/291/30
Most frequent other events
Most frequent other events
EventDexamethasone Punctum PlugPlacebo Vehicle Punctum Plug
Eye disordersEye disorders3/2910/30

Baseline characteristics

Age, Customized
Age, Customized(Participants)Dexamethasone Punctum PlugPlacebo Vehicle Punctum PlugTotal
Age between 21 - 6514923
Age greater than or equal to 65162137
Sex: Female, Male
Sex: Female, Male(Participants)Dexamethasone Punctum PlugPlacebo Vehicle Punctum PlugTotal
Female171229
Male131831
08

Study locations

1 site
  • Chicago Cornea Consultants, Ltd.
    Hoffman Estates, Illinois 60169, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2012 to primary completion in Aug 2013, 10 months.

Results were first posted in Apr 2017, 3 years 8 months after primary completion.

Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 10 months is above that.

Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2012
First posted
Aug 16, 2012
StartActual
Oct 2012
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Apr 27, 2017
Last update
Oct 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01666210
Responsible party
Sponsor
First posted
Aug 16, 2012
Start date
Oct 2012
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Apr 27, 2017
Last update
Oct 19, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion